Oral treprostinil in the treatment of pulmonary arterial hypertension

References

• Patel BB, Feng Y, Cheng-Lai A. Pulmonary arterial hypertension: a review in pharmacotherapy. Cardiol Rev. 2015;23(1):33–51.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from the time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest J. 2012;142(2):448–456.
   PubMed Web of Science ®Google Scholar
• Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Resp Rev. 2013;22(129):217–226.
   PubMedGoogle Scholar
• Mclaughlin VV, Shillington A, Rich S. Survival in primary PH: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482.
   PubMed Web of Science ®Google Scholar
• White RJ, Levin Y, Wessman K, et al. Subcutaneous treprostinil is well tolerated with infrequent site changes and algesics. Pulm Circ. 2013;3(3):611–621.
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins (review). Clinics Chest Med. 2001;22(3):529–537.
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Rabasseda X, Castaner J. UT-15 (review). Drugs Fut. 2001;26(4):364–374.
   Web of Science ®Google Scholar
• Channick RN, Rubin LJ. New and experimental therapies for pulmonary hypertension (review). Clinics Chest Med. 2001;22(3):539–545.
   PubMed Web of Science ®Google Scholar
• Orenitram U.S. package insert. Research Triangle Park: United Therapeutics Corporation. 2016.
   Google Scholar
• Kumar P, Thudium E, Laliberte K, et al. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. 2016;55:1495–1505.
   PubMed Web of Science ®Google Scholar
• White RJ, Torres F, Allen R, et al. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2013;61(6):474–481.
   PubMed Web of Science ®Google Scholar
• Jenkins A, Wang-Smith L, Marbury T, et al. Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. J Cardiovasc Pharmacol. 2013;61(4):272–276.
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 5;127(5):624–633.
   PubMed Web of Science ®Google Scholar
• Jones A, Wang-Smith L, Pham T, et al. Pharmacokinetics of 3 times a day dosing of oral treprostinil in health volunteers. J Cardiovasc Pharmacol. 2014;63:227–232.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383–1390.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952–958.
   PubMed Web of Science ®Google Scholar
• White RJ, Rao Y. Novel analysis of the oral treprostinil combination therapy data. Am J Respir Crit Care Med. 2016 15; 193(12):1434–1436.
   PubMed Web of Science ®Google Scholar
• Fares WH. Reply: oral treprostinil combination trials post hoc secondary analyses: a step toward verifying its efficacy. Am J Resp Crit Care Med. 2016;193(12):1437–1438.
   PubMed Web of Science ®Google Scholar
• Chin KM, Ruggiero R, Bartolome S, et al. Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center. Pulm Circ. 2015;5(3):513–520.
   PubMed Web of Science ®Google Scholar
• Gleason JB, Dolan J, Piran P, et al. The rapid initiation, titration, and transition from intravenous to oral treprostinil in a patient with severe pulmonary arterial hypertension. Case Rep Pulmonol. 2015;2015: 498981. Epub 2015 Sep 17. DOI:10.1155/2015/498981
   Google Scholar
• Coons JC, Miller T, Simon MA, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case report and series and treatment protocol. Pulm Circ. 2016 Mar;6(1):132–135.
   PubMed Web of Science ®Google Scholar
• Chakinala MM, Feldman JP, Rischard F, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant. 2017 Feb;36(2):193–201.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015 Dec 24;373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li X, Huang J, et al. Comparative efficacy and safety of prostacyclin analogs for pulmonary arterial hypertension: a network meta-analysis. Medicine (Baltimore). 2016 Jan;95(4):e2575.
   PubMed Web of Science ®Google Scholar
• Jansen J, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:150.
   PubMed Web of Science ®Google Scholar
• Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015 Aug 27;373(9):834–844.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809–818.
   PubMed Web of Science ®Google Scholar